Centessa Pharmaceuticals (CNTA) Enterprise Value (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Enterprise Value for 4 consecutive years, with -$294.6 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 38.91% to -$294.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$294.6 million through Dec 2025, up 38.91% year-over-year, with the annual reading at -$294.6 million for FY2025, 38.91% up from the prior year.
  • Enterprise Value for Q4 2025 was -$294.6 million at Centessa Pharmaceuticals, down from -$246.2 million in the prior quarter.
  • The five-year high for Enterprise Value was -$230.2 million in Q1 2024, with the low at -$544.5 million in Q1 2022.
  • Average Enterprise Value over 4 years is -$353.5 million, with a median of -$299.2 million recorded in 2023.
  • The sharpest move saw Enterprise Value crashed 87.95% in 2024, then soared 52.51% in 2025.
  • Over 4 years, Enterprise Value stood at -$393.6 million in 2022, then skyrocketed by 34.83% to -$256.5 million in 2023, then plummeted by 87.95% to -$482.2 million in 2024, then surged by 38.91% to -$294.6 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$294.6 million, -$246.2 million, and -$250.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.